Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $675,631.45 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 2,951 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $228.95, for a total transaction of $675,631.45. Following the completion of the transaction, the insider owned 123,499 shares in the company, valued at approximately $28,275,096.05. The trade was a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total transaction of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $193,858.56.
• On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The stock was sold at an average price of $187.95, for a total transaction of $54,881.40.

Natera Trading Down 5.8%

Shares of NTRA stock opened at $239.56 on Friday. The stock’s fifty day simple moving average is $226.34 and its 200-day simple moving average is $185.64. The company has a market capitalization of $33.14 billion, a price-to-earnings ratio of -104.61 and a beta of 1.62. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.26) EPS. On average, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent analyst reports. Guggenheim lifted their price objective on Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday. BTIG Research raised their target price on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Barclays increased their price target on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Evercore ISI boosted their price objective on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, Stephens lifted their target price on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Sixteen research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $238.89.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NTRA. Siemens Fonds Invest GmbH lifted its holdings in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares during the last quarter. Guided Capital Wealth Management LLC increased its position in Natera by 0.5% during the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after purchasing an additional 66 shares in the last quarter. BOKF NA increased its holdings in Natera by 1.9% in the 3rd quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock worth $601,000 after purchasing an additional 69 shares in the last quarter. Silvant Capital Management LLC grew its holdings in Natera by 0.5% during the 3rd quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company’s stock worth $2,171,000 after acquiring an additional 70 shares during the last quarter. Finally, Main Management ETF Advisors LLC lifted its holdings in Natera by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after buying an additional 72 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Major banks initiate or reaffirm buy ratings on Natera, which can attract more institutional demand and support the stock. Citigroup initiates coverage of Natera (NTRA) with buy recommendation
• Positive Sentiment: Piper Sandler issued a buy on Natera, reinforcing recent bullish analyst activity and signaling continued confidence in the company’s growth trajectory. Natera (NTRA) Receives a Buy from Piper Sandler
• Positive Sentiment: Guggenheim reiterated its buy rating, joining other firms that have raised price targets — a supportive backdrop for sentiment and mid‑term upside. Guggenheim Sticks to Their Buy Rating for Natera (NTRA)
• Positive Sentiment: Natera announced a collaboration with Exelixis on the phase 3 STELLAR‑316 colorectal cancer trial — this expands potential clinical use cases for Natera’s oncology assays and could drive future revenue if tied to companion diagnostics/monitoring. Exelixis and Natera to Collaborate on STELLAR-316
• Neutral Sentiment: Analyst consensus remains skewed positive overall (MarketBeat/AmericanBankingNews show a “Moderate Buy” average rating and a consensus price target in the low‑to mid‑$200s), implying expectations are baked into current levels. Natera, Inc. (NASDAQ:NTRA) Receives Average Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Routine market data/price pages track the share move but add no new catalyst. Natera (NTRA) share price
• Negative Sentiment: Significant insider selling was reported (aggregate reports note roughly US$47M in insider sales recently), which can signal near‑term liquidity or confidence concerns and often pressures the stock. Insiders At Natera Sold US$47m In Stock
• Negative Sentiment: Company insiders including CEO Steven Chapman and other executives (Solomon Moshkevich) recently filed Form 4 sales (small single‑digit percentage reductions in holdings). Multiple, recurring insider sales can amplify investor caution. Solomon Moshkevich Sells 2,951 Shares of Natera (NASDAQ:NTRA) Stock

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.